<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779571</url>
  </required_header>
  <id_info>
    <org_study_id>86-814d 6.2008.453</org_study_id>
    <nct_id>NCT00779571</nct_id>
  </id_info>
  <brief_title>The Female Health Dietary Intervention Study</brief_title>
  <acronym>FEMIN</acronym>
  <official_title>Treatment of PCOS (Polycystic Ovary Syndrome)in Morbidly Obese Women - A Randomized Controlled Prospective Dietary Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital of Vestfold</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has two phases:

        1. In phase 1 of the study (8 weeks),the effect of two different low calorie diets on
           manifestations of PCOS, including risk factors for the metabolic syndrome and
           cardiovascular risk profile will be compared.

        2. In phase 2 the long term effect (next 44 weeks) on sustained weight-loss and the above
           mentioned parameters will be compared and evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Weight loss is an important and effective treatment of morbidly obese women with PCOS.
      Effective weight reduction will improve manifestations of PCOS and risk factors for
      developing type 2 diabetes and coronary heart diseases. We compare the effect of two
      isocaloric low calorie diets (LCD), - one powder-based shake-diet and a fiber rich diet on
      the above mentioned parameters. In addition we want to compare the weight-maintenance effect
      the next 44 weeks of two different follow-up programs: A usual care- and a lifestyle-program.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of PCOS, diabetes type 2- and coronary heart disease-risk factors</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Crispbread</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Crispbread LCD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid meal replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: LMR LCD</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Crispbread</intervention_name>
    <description>8 week low calorie diet</description>
    <arm_group_label>Crispbread</arm_group_label>
    <arm_group_label>Liquid meal replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman (European Caucasian)

          -  PCOS

          -  BMI = or &gt; 35

        Exclusion Criteria:

          -  Cushing syndrome

          -  Adrenal hyperplasia

          -  Androgen-producing tumors

          -  Anovulation caused by hyperprolactinemia

          -  Pregnancy, breast feeding

          -  Use of oral contraceptives/hormone treatment/insulin-sensitizing agents
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jøran Hjelmesæth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital of Vestfold</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Tanbo, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kirsten B Holven, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Line Kristin Johnson, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kvinneklinikken, Rikshospitalet-Radiumhospitalet HF</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital of Vestfold</investigator_affiliation>
    <investigator_full_name>Line Kristin Johnson</investigator_full_name>
    <investigator_title>MSc, PhD</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Morbid Obesity</keyword>
  <keyword>Type 2 DM</keyword>
  <keyword>Coronary heart disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

